HOUSTON and VANCOUVER, Jan. 16, 2018 /PRNewswire/ – ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) (“ESSA” or the “Company”) announced today that it expects to receive a letter (the “Nasdaq Notice”) from the Nasdaq Stock Market (“Nasdaq”), granting the Company an additional 180-day period, or…
